$1,318.00
This Market Spotlight report covers the insomnia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming events and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
This Market Spotlight report covers the Insomnia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Subtypes
8 TREATMENT
8 Non-medical treatments
8 Medical treatments
11 EPIDEMIOLOGY
15 MARKETED DRUGS
19 PIPELINE DRUGS
23 RECENT EVENTS AND ANALYST OPINION
23 Sunobinop for Insomnia (December 12, 2022)
25 KEY REGULATORY EVENTS
25 CHMP Recommends Pan-EU Approval For Melatonin Neurim
25 Stada Wins Battle To Keep Hoggar Night Sleep Aid OTC In Germany
25 EMA Thumbs Up For Idorsia’s Insomnia Drug
25 Idorsia In Dreamland With Insomnia Drug Approval
27 PROBABILITY OF SUCCESS
28 LICENSING AND ASSET ACQUISITION DEALS
28 Sumitomo Divests Lunesta To Woodward, Excluding Canada
28 Simcere Gets China Rights For Idorsia’s Daridorexant
29 REVENUE OPPORTUNITY
31 CLINICAL TRIAL LANDSCAPE
32 Sponsors by status
33 Sponsors by phase
35 BIBLIOGRAPHY
36 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in prevalent cases of insomnia, 2021–30
19 Figure 2: Overview of pipeline drugs for insomnia in the US
19 Figure 3: Pipeline drugs for insomnia, by company
19 Figure 4: Pipeline drugs for insomnia, by drug type
20 Figure 5: Pipeline drugs for insomnia, by classification
24 Figure 6: Sunobinop for Insomnia (December 12, 2022): Phase II – OAG2002
27 Figure 7: Probability of success in the insomnia pipeline
31 Figure 8: Clinical trials in insomnia
31 Figure 9: Top 10 drugs for clinical trials in insomnia
32 Figure 10: Top 10 companies for clinical trials in insomnia
32 Figure 11: Trial locations in insomnia
33 Figure 12: Insomnia trials status
34 Figure 13: Insomnia trials sponsors, by phase
LIST OF TABLES
12 Table 1: Prevalent cases of insomnia, 2021–30
16 Table 2: Marketed drugs for insomnia
21 Table 3: Pipeline drugs for insomnia in the US
23 Table 4: Sunobinop for Insomnia (December 12, 2022)
29 Table 5: Historical global sales, by drug ($m), 2017–21
30 Table 6: Forecasted global sales, by drug ($m), 2023–27
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!